3 Stocks Set to Beat the S&P Today

LONDON -- European equity markets are seeing another day of losses Wednesday, directed form the outset by overnight trading in Asia, where stocks were under pressure following disappointing Chinese manufacturing data. The HSBC Flash China manufacturing purchasing managers' index showed that the country's factory production is continuing to slow, although it did climb slightly to 47.8 from 47.6 last month, increasing concerns of economic slowdown and the impact of recovery and stimulus measures. Early trade shows that Wall Street is likely to follow the European markets at the open, with the S&P 500 (INDEX: ^GSPC  ) down almost 0.5%.

Despite this broad weakness, there are, as always, some individual names outperforming. Here are three American depositary receipts that are set to beat the S&P today.

Coca-Cola Hellenic Bottling (NYSE: CCH  )
The bottling giant is up almost 3% in Athens today, bolstered after it was included in the 2012 Dow Jones Sustainability Index for the fourth consecutive year. This lists the company as one of the world's top beverage companies by sustainability, being just one of four beverage companies in the index. This comes days after news the company is looking at options for listing its stock on other exchanges, including a potential move to London as its primary listing, which may well see it included in the FTSE 100 index of largest British companies.

Ryanair Holdings (Nasdaq: RYAAY  )
The Irish budget airline is up 1.3% Wednesday thanks to findings by the country's aviation authority. It was concluded that Ryanair planes that had been diverted because of bad weather in Madrid, forcing them to declare emergencies due to low fuel, had set off with sufficient amounts of kerosene in excess of flight-plan requirements. Although levels were found to be approaching minimum levels by the time the three planes landed, there was no immediate danger.

Grifols (Nasdaq: GRFS  )
The Spanish maker of plasma derivative products and services is up 1.2% today, continuing to benefit from news earlier this week that it will expand its North American. Grifols' subsidiary, Biomat USA, will purchase three U.S. plasma donation centers from Cangene, although the exact terms of the deal have not yet been made public.

Despite the ongoing eurozone troubles, this morning's European trading did provide some winners -- and perhaps some European buying opportunities. Indeed, legendary investor Warren Buffett has recently spent more than $1 billion buying the stock of a prominent European large cap.

If you want to know why Buffett has bought into Europe, this special Motley Fool report -- "The One European Share Warren Buffett Loves" -- reveals everything, including the price he paid. You can download the report today for free, but hurry -- the report is available for a limited time only.

The Motley Fool is helping Europe invest. Better. And with the eurozone economy so uncertain, we're urging everyone to read "10 Steps To Making A Million In The Market" -- this report may transform your wealth. Click here now to request your free, no-obligation copy.

Further Motley Fool investment opportunities:

Karl Loomes does not own any share mentioned in this article. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2024624, ~/Articles/ArticleHandler.aspx, 7/23/2014 5:27:24 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement